This title appears in the Scientific Report :
2023
Please use the identifier:
http://dx.doi.org/10.1038/s41531-023-00458-4 in citations.
Please use the identifier: http://hdl.handle.net/2128/33955 in citations.
Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive a...
Saved in:
Personal Name(s): | Schaffrath, Anja |
---|---|
Schleyken, Sophia / Seger, Aline / Jergas, Hannah / Özdüzenciler, Pelin / Pils, Marlene / Blömeke, Lara / Cousin, Anneliese / Willbold, Johannes / Bujnicki, Tuyen / Bannach, Oliver / Fink, Gereon R. / Willbold, Dieter / Sommerauer, Michael / Barbe, Michael T. / Tamgüney, Gültekin (Corresponding author) | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 Strukturbiochemie; IBI-7 |
Published in: | npj Parkinson's Disease, 9 (2023) 1, S. 14 |
Imprint: |
London [u.a.]
Nature Publ. Group
2023
|
DOI: |
10.1038/s41531-023-00458-4 |
Document Type: |
Journal Article |
Research Program: |
SFB 1451: Schlüsselmechanismen normaler und krankheitsbedingt gestörter motorischer Kontrolle Information Processing in Neuronal Networks |
Link: |
OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/33955 in citations.
Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies. |